- Home
- CGEN vs AGEN Comparison
CGEN vs AGEN Comparison
Compare CGEN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEN | AGEN |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 126.2M |
| IPO Year | 2001 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CGEN | AGEN |
|---|---|---|
| Price | $2.26 | $3.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $14.50 |
| AVG Volume (30 Days) | 303.3K | ★ 372.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | $58.57 | $68.25 |
| P/E Ratio | ★ N/A | $8.05 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $1.13 | $1.38 |
| 52 Week High | $2.38 | $7.34 |
Technical Indicators
Market Signals| Indicator | CGEN | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 63.91 | 48.05 |
| Support Level | $1.45 | $2.92 |
| Resistance Level | $2.36 | $3.15 |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 85.60 | 29.69 |
Price Performance
Historical ComparisonAbout CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).